Wedbush analyst Ygal Arounian downgrades Zillow Gr (NASDAQ:ZG) from Outperform to Neutral.
Seagen, RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin; Seagen to Make $200M Upfront Payment to License Rights to Disitamab Vedotin
Seagen Inc. (Nasdaq: SGEN) and RemeGen Co., Ltd. (9995.HK), a leading innovative biopharmaceutical company in China, today announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC.
